CD30 biAb-AATC
/ Medical College of Wisconsin, Tundra Targeted Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 27, 2025
CD30biAb-AATC for CD30+ Malignancies
(clinicaltrials.gov)
- P1 | N=42 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Phase classification: P1/2 ➔ P1 | Trial completion date: Jan 2027 ➔ Jul 2028
Phase classification • Trial completion date • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8
September 19, 2022
CD30biAb-AATC for CD30+ Malignancies
(clinicaltrials.gov)
- P1/2 | N=42 | Not yet recruiting | Sponsor: Medical College of Wisconsin
New P1/2 trial • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Germ Cell Tumors • Hematological Malignancies • Leukemia • Lymphoma • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Sarcoma • Solid Tumor • CSF2 • TNFRSF8
1 to 2
Of
2
Go to page
1